NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ardent Health, Inc. ("Ardent Health, Inc." or the "Company") (NYSE: ARDT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ardent Health, Inc. investors who were adversely affected by alleged securities fraud between July 18, 2024 and November 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/ar ...

Core Viewpoint - A class action securities lawsuit has been filed against Oracle Corporation, alleging securities fraud that negatively impacted investors between June 12, 2025, and December 16, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [2]. - It is alleged that the increased spending poses serious risks to Oracle's debt and credit rating, free cash flow, and ability to fund projects [2]. - The representations made by the defendants regarding Oracle's business operations and prospects are claimed to be materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until April 6, 2026, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Bath & Body Works, Inc. alleging securities fraud that affected investors between June 4, 2024, and November 9, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that the company's strategy of pursuing "adjacencies, collaborations and promotions" failed to grow the customer base and did not deliver the expected growth in net sales [2] - It is alleged that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results [2] - The complaint states that the company was unlikely to meet its previously issued financial guidance due to these issues, rendering positive statements about its business misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 13, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Deadline Approaching: PayPal Holdings, Inc. (PYPL) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithFeb 19, 2026 2:52 PM Eastern Standard Time# Deadline Approaching: PayPal Holdings, Inc. (PYPL) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithShare---BENSALEM, Pa.--([BUSINESS WIRE])--Law Offices of Howard G. Smith reminds investors of the upcoming April 20, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchase ...

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1] Summary by Relevant Sections Class Action Lawsuit Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1] - The lawsuit alleges that Ultragenyx and its executives made false statements and failed to disclose critical information about the Phase III Orbit study, which did not achieve statistically significant results [1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a false impression of having reliable data on setrusumab's effects while downplaying the risks associated with the Phase III Orbit study [1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study failed to achieve statistical significance, leading to a stock price drop of over 25% [1] - Further, on December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies did not meet primary endpoints, resulting in a stock price decline of more than 42% [1] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek lead plaintiff status, representing the interests of all class members [1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1]

Kyndryl Holdings, Inc. (KD) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy KD securities between August 7, 2024, and February 9, 2026?Affected Kyndryl Holdings, Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Great Elm Capital Corp. regarding possible recovery of investor losses under federal securities laws due to the company's statements about its exposure to First Brands Capital Group LLC following First Brands' bankruptcy [1][3]. Group 1: Investigation Details - The investigation focuses on whether Great Elm Capital's executive officers made misleading statements about the company's financial exposure related to First Brands Capital Group LLC [3]. - Investors who purchased Great Elm Capital securities and suffered losses are encouraged to join the investigation [2]. Group 2: About Johnson Fistel, PLLP - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with offices across multiple states [4]. - The firm has a strong track record, having recovered approximately $90.725 million for clients in securities class action lawsuits, and has been recognized as a top plaintiffs' securities law firm multiple times [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines after revelations of financial discrepancies [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it involves purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025 [1]. - Investors have until March 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims violations of the Securities Exchange Act of 1934 by Ardent Health and its executives [1]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, leading to inflated financial reports [3]. - It is claimed that Ardent Health's accounts receivable framework allowed for delayed recognition of losses, resulting in materially misleading financial positions [3]. - The company allegedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in the New Mexico market [3]. Group 3: Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third-quarter revenue due to revised accounts receivable collectability assessments [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4].

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. on behalf of investors who acquired its securities during the specified Class Period, highlighting potential legal challenges for the company [1][2]. Group 1: Company Overview - Beyond Meat, headquartered in El Segundo, California, is a developer of plant-based food products, selling meat alternatives under the "Beyond" brand both domestically and internationally [2]. Group 2: Financial Performance and Challenges - As market conditions deteriorated, Beyond Meat committed to achieving EBITDA-positive operations by the end of 2026, focusing on expense reduction, margin improvement, and operational efficiency [3]. - On October 24, 2025, Beyond Meat announced an expected material impairment charge, leading to a stock price drop of over 23% in one trading day [4]. - Subsequent disclosures in November 2025 regarding delayed SEC filings and $77.4 million in impairment charges resulted in further stock declines of approximately 16%, 9%, and 9%, causing significant investor losses [4].

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. (NASDAQ: METC) for allegedly misleading investors about the development progress of its projects, particularly the Brook Mine in Wyoming, leading to a significant drop in stock price following the revelation of these claims [1]. Company Overview - Ramaco Resources, Inc. is headquartered in Lexington, Kentucky, and operates coal and mineral development projects in the United States [1]. Lawsuit Details - The lawsuit pertains to investors who purchased Ramaco securities between July 31, 2025, and October 23, 2025, with a deadline of March 31, 2026, for potential lead plaintiff appointments [1]. - The complaint alleges that Ramaco overstated development progress at the Brook Mine, which was described as a "hoax" and a "Potemkin Mine" by Wolfpack Research, indicating no significant mining activity had occurred since its groundbreaking [1]. Stock Market Impact - Following the report by Wolfpack Research on October 23, 2025, Ramaco's stock price fell by $3.81, nearly 10%, closing at $36.01 per share, with unusually high trading volume [1].